Free Trial
Yale Jen

Yale Jen Analyst Performance

Senior Managing Director, Senior Biotech Analyst at Laidlaw

Yale Jen is a stock analyst at Laidlaw in the healthcare sector, covering 11 publicly traded companies. Over the past year, Yale Jen has issued 5 stock ratings, including buy and hold recommendations. While full access to Yale Jen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yale Jen's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 11 Years
Buy Recommendations
91.67% 11 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy91.7%11 ratings
Hold8.3%1 ratings
Sell0.0%0 ratings

Out of 12 total stock ratings issued by Yale Jen at Laidlaw, the majority (91.7%) have been Buy recommendations, followed by 8.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
90.9% of companies on NASDAQ
10 companies
NYSEAMERICAN
9.1% of companies on NYSEAMERICAN
1 company

Yale Jen, an analyst at Laidlaw, currently covers 11 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
11 companies
100.0%

Yale Jen of Laidlaw specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
5 companies
45.5%
PHARMACEUTICALS
4 companies
36.4%
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
18.2%

About Yale Jen

Dr. Jen joined Laidlaw & Co. in September 2013 as Managing Director, Biotechnology Analyst. He has over ten years of Wall Street healthcare analyst experience. Prior to joining Laidlaw, he was a Senior Equity Analyst at Roth Capital Partners focusing on biotechnology since February 2012; and before that – a Senior Equity Analyst focusing on biotechnology and China healthcare at Maxim Group since November 2007. Prior, he was an associate analyst at Rodman and Renshaw and Thomas Weisel Partners covering large as well as mid to small cap biotechnology and specialty pharmaceutical companies. His investment views have been cited in the Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswire. Before joining Wall Street, Yale spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions of healthcare assets, as well as on pipeline optimization for pharmaceutical and biotechnology clients. Dr. Jen received his Ph.D. in molecular biology from Cornell Medical School and his MBA from Rutgers University with a concentration in finance. He holds FINRA licenses: 7, 63, 86 and 87.
Follow on LinkedIn

Yale Jen's Ratings History at Laidlaw

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
10/20/2026Downgrade$0.45Hold
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
7/13/2026Initiated Coverage$4.19$23.00Buy
Novogen Limited stock logo
KZIA
Novogen
4/15/2026Initiated Coverage$9.46$25.00Buy
Palatin Technologies stock logo
PTN
Palatin Technologies
12/12/2025Initiated Coverage$24.67$60.00Buy
Femasys Inc. stock logo
FEMY
Femasys
11/20/2025Initiated Coverage$15.18$130.00Buy
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
6/6/2025Initiated Coverage$3.56$5.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3/27/2025Boost Price Target$68.01$105.00Buy
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3/17/2025Initiated Coverage$8.85$19.00Buy
Lifeward Ltd. stock logo
LFWD
Lifeward
2/10/2025Initiated Coverage$16.80$120.00Buy